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Abstract
Background: The MET receptor tyrosine kinase represents a promising target in cancer. PIK3CA activating
mutations are common in several tumor types and can potentially confer resistance to anti-receptor tyrosine kinase
therapy.
Methods: MET and/or PI3K pathway inhibition was assessed in NIH3T3 cells harboring MET-activating point
mutation with or without ectopic expression of PIK3CAE545K and PIK3CAH1047R, as well as in MET-expressing head
and neck cancer cells with endogenous PIK3CA mutations. Endpoints included PI3K pathway activation, cell
proliferation, colony-forming ability, cell death, wound-healing, and an in vivo model.
Results: PIK3CAE545K and PIK3CAH1047R confer resistance to MET inhibition in MET-driven models. PIK3CAH1047R was
more potent than PIK3CAE545K at inducing resistance in PI3K pathway activation, cell proliferation, colony-forming
ability, induction of cell death and wound-healing upon MET inhibition. Resistance to MET inhibition could be
synergistically overcome by co-targeting PI3K. Furthermore, combined MET/PI3K inhibition led to enhanced anti-
tumor activity in vivo in tumors harboring PIK3CAH1047R. In head and neck cancer cells the combination of MET/PI3K
inhibitors led to more-than-additive effects.
Conclusions: PIK3CA mutations can lead to resistance to MET inhibition, supporting future clinical evaluation of
combinations of PI3K and MET inhibitors in common scenarios of malignant neoplasms featuring aberrant MET
expression and PIK3CA mutations.
Keywords: MET receptor tyrosine kinase, PI3K pathway, PIK3CA mutations, Resistance mechanisms, Head and neck
cancer
Background
MET is the receptor tyrosine kinase (RTK) for scatter
factor/hepatocyte growth factor (SF/HGF). Aberrant
activation of the SF/HGF-MET axis is common in a
wide range of human malignancies and promotes cell
growth, invasiveness, metastatic potential, angiogenesis,
and resistance to cell death following chemotherapy
and radiotherapy [1–7]. The established relevance of SF/
HGF-MET in tumorigenesis and progression suggests that
MET inhibition is a potential strategy in cancer therapy, a
notion supported by a growing body of preclinical evidence.
Moreover, several strategies to impair SF/HGF-MET aber-
rant activation are currently under investigation in numer-
ous clinical trials [7, 8], and cabozantinib (MET, RET, and
VEGFR2 multikinase inhibitor) received FDA approval for
the treatment of medullary thyroid carcinoma [9].
Paralleling the preclinical and clinical developments in
the field of RTK-targeted therapy, awareness on potential
mechanisms of therapeutic resistance is an issue of major
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relevance. One such resistance mechanism is the presence
of activating mutations affecting different members of sig-
naling pathways downstream of RTKs, such as the MAPK
and the PI3K pathways. The actual clinical relevance of
this phenomenon was clearly outlined by Karapetis et al.
[10], who assessed the impact of activating mutations in
exon 2 of KRAS in cetuximab-treated patients with colo-
rectal cancer. The authors found that 42.3% of the tumors
harbored at least one KRAS mutation. Cetuximab was
beneficial in terms of overall survival only in patients
with wild-type KRAS. In order to optimize patient
selection in this subgroup of patients, assessment of
KRAS mutational status is currently performed prior to
cetuximab therapy [10]. In a later study, Douillard et al.
demonstrated that other KRAS mutations (exon 3 and 4)
equally had an impact on responses to panitumumab in
patients with colorectal cancer [11].
Mutations along the MAPK pathway are well-established
sources of resistance to RTK inhibitors, particularly against
EGFR targeted therapies [12]. Importantly however, recent
comprehensive genomic approaches have revealed a high
prevalence of mutations in members of the PI3K pathway
in various human cancer types, including head and neck
cancer (HNC), breast cancer, or endometrial carcinoma
[13–15]. These mutations are most commonly encoun-
tered in the PIK3CA-encoded p110α catalytic subunit
of PI3K (PIK3CA) and tend to cluster at hotspots E542
and E545 within the helical domain, as well as H1047
in the kinase domain. Previous in vitro studies have
shown that PIK3CA hotspot mutations lead to in-
creased kinase activity and confer variable oncogenic fea-
tures [14, 16]. More specifically, Meyer et al. showed that
both PIK3CAE545K and PIK3CAH1047R were tumorigenic
in mouse mammary models [17]. However, PIK3CAE545K-
induced tumors developed more slowly and were histolog-
ically less aggressive than PIK3CAH1047R-driven tumors.
In contrast to these findings in mammary tumors, Trejo et
al. [18] reported that presence of PIK3CAH1047R alone was
not sufficient to promote initiation in lung cancer models.
Instead, co-presence of BRAFV600E was required for initi-
ation. In such context both mutations cooperated in
tumor progression.
The PI3K-AKT-mTOR pathway is a critical regulator
of cell metabolism, proliferation, survival, apoptosis
and cell motility [19]. PI3K activity can be countered
by its negative regulator phosphatase and tensin
homologue (PTEN), whose loss-of-function is com-
mon in cancer [20]. Upon PI3K activation, AKT is re-
cruited to the cell membrane and phosphorylated. In
turn, phosphorylated AKT activates an extensive sig-
naling network, resulting in cell growth by promoting
ribosome biogenesis, protein translation, synthesis of
lipids and nucleotides, and regulation of autophagy
[13, 21]. Moreover, AKT exerts a pro-survival activity
by phosphorylating MDM2 and thus inhibiting p53-
regulated cell-cycle arrest and apoptosis [19, 22].
The implications of synchronous presence of aberrantly
active MET and PIK3CA mutations in cancer has not
been previously explored. Therefore, we hypothesized that
in preclinical models of MET-driven tumors sensitive to
MET inhibition, PIK3CA mutations may confer resistance
to MET inhibition. Our data demonstrate that PI3K
signaling remains active upon MET inhibition in tumors
harboring PIK3CA mutations, rendering such tumors
resistant to MET inhibition. In vivo tumor models harbor-
ing PIK3CAH1047R are equally more resistant to MET
inhibition than their wild-type counterpart. In all cases,
PIK3CA-induced resistance to MET inhibitors could be
reverted by co-targeting PI3K.
Complementarily, we sought to assess the impact of
dual MET/PI3K inhibition in models displaying ligand-
induced MET activation and PI3K mutations. For this
purpose, we selected cellular models of HNC endogen-
ously harboring PIK3CA mutations. In this particular
disease, PIK3CA are commonly encountered (over one-
third of cases), in contrast with the more seldom MAPK
or JAK/STAT mutations [23]. Moreover, MET gene copy
number gain or amplification is found in around 20% of
HNCs, and protein overexpression in more than 80% of
the cases [4]. However, MET constitutive activation is
rare in HNC, and receptor activation occurs mainly
through oncogenic ligand-receptor loops [24]. In HNC
models, combination of MET and PI3K inhibitors was
effective in abrogating invasive features regardless of
PIK3CA mutational status, but had synergistic effects
especially in PIK3CA-mutated cell lines.
Methods
Cell lines, plasmids and transfections
NIH3T3 cells stably expressing MET-activating mutation
M1268T were provided by Dr. Laura Schmidt (NCI,
Frederick, MD, USA) and maintained as previously
described [25].
NIH3T3 MET M1268T cells were transfected using
standard reverse transfection protocols with Lipofecta-
mine 2000 (Invitrogen), using the following plasmids:
PIK3CA E545K and H1047R (Addgene plasmids #12524
and #12525 respectively, from Jean Zhao [26]), as well as
pBABE control vector (Addgene plasmid #14738,from
Adrienne Cox [27]). Stable transfectants were selected in
the presence of puromycin (1.5 μg/mL).
HNC cell lines FaDu (PIK3CA wild-type) and Detroit-
562 (PIK3CA H1047R) were obtained from the American
Type Culture Collection (Manassas, VA, USA) and
cultured in Minimum Essential Medium (MEM, Sigma)
supplemented with FCS 10%, antibiotic-antimycotic, and
non-essential aminoacids (NEAA 1% vol/vol; Sigma).
SCC-61 (PIK3CA E542K) cells were provided by Prof. M.
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Pruschy (University of Zurich, Switzerland) and cultured
in DMEM with supplements [28, 29]. No cell line authen-
tication was performed by the authors for this study.
Inhibitors and growth factor treatments
The MET tyrosine kinase inhibitor tepotinib (EMD1214063,
MSC2156119J) was kindly provided by Merck KGaA
(Darmstadt, Germany). PI3K was inhibited with pictilisib
(GDC-0941; AbMole BioScience, Hong Kong). Both drugs
were dissolved in DMSO and stored at−20 °C. DMSO
concentrations were normalized in all experimental
conditions.
Recombinant human SF/HGF was purchased from
R&D Systems and prepared following the manufacturer’s
instructions. Treatments were carried out as described
in Results.
Immunoblotting and immunoprecipitation
Cells were lysed with Non-ident NP40 buffer as previously
described [25]. Xenograft tissues were lysed similarly,
including a previous step of mechanical disruption. Total
protein concentrations were determined with the Bio-Rad
protein quantification reagent (Bio-Rad Laboratories,
Inc.). Equal amounts of protein (30–50 μg) were resolved
by SDS-PAGE on 7–12% gels under reducing conditions.
Separated proteins were transferred onto PVDF mem-
branes, blocked with 5% milk or BSA in TBS/T, and
incubated overnight with the following primary anti-
bodies: p-Y1234/Y1235 MET, p-Ser473 AKT, p-Thr202/
Tyr204 ERK1/2, p-Ser235/236 S6, pan-AKT, and pan ERK
(all from Cell Signaling Technology). Anti-β-actin anti-
body was obtained from Millipore Corporation. The anti-
HA high affinity antibody (clone 3 F10) was purchased
from Roche.
Membranes were incubated with appropriate secondary
antibodies and signals were detected with the ECL kit
(Amersham Pharmacia Biotech) or with infrared fluores-
cence on an Odyssey imager (Li-Cor biosciences).
Immunoprecipitation was performed using the Dyna-
beads® Protein G kit following manufacturer’s instructions
(ThermoFisher Scientific, #10003D).
With the exception of samples from in vivo tumors
and organotypic slices, immunoblots shown are repre-
sentative of at least three independent experiments.
Cell viability/toxicity assays, determination of EC50 values
and combinatorial effects
Cell viability was determined using a resazurin sodium salt
reduction assay (Sigma). Briefly, after treatment for 48 h,
cells were supplemented with medium containing 44 μM
resazurin. Resazurin reduction was colorimetrically mea-
sured 1 and 6 h later (570/600 nm) with a Tecan Reader
(Tecan Group Ltd.). Results were normalized to vehicle-
treated controls and represent the mean of at least three
independent experiments.
For half maximal effective concentration (EC50) value
determination, resazurin assays were carried out after
72 h of treatment with increasing doses of tepotinib and
pictilisib (0 to 10 μM). EC50 values were determined
using the GraphPad software (version 5.03).
The combinatorial effects between MET and PI3K in-
hibition were estimated by Bliss independence analyses
as previously described [30]. Excess over Bliss values
equal to 0 indicate additive effects, >0 activity greater-
than-additive, and <0 combination less-than-additive.
Cell death and viability were assessed with the Live/
Dead Assay Kit (Molecular Probes). For this assay, cells
were treated for 3 days and stained with green-fluorescent
calcein-AM (viable cells) and red-fluorescent ethidium
homodimer-1 (dead cells). Images from four independent
experiments were captured under a fluorescent micro-
scope (Leica DC 300 F) and number of live and dead cells
quantified using ImageJ (imagej.nih.gov/ij/).
Caspase-3 enzymatic activity was determined via a
fluorogenic assay based on the caspase-3 specific substrate
Ac-DEVD-AMC (Calbiochem). The substrate was added
to cell lysates after 72 h of treatment and fluorescence was
measured at excitation and emission wavelengths of
380 nm and 460 nm respectively, with an Infinite 200
plate reader (Tecan Group Ltd.). Caspase-3 activity was
normalized to protein content and results shown are rep-
resentative of at least three independent experiments.
Colony-forming assays
Cells were plated the day before treatment at densities
ranging from 500 to 2500 cells/well in 6-well plates and
then treated with the indicated drug concentrations. Col-
onies were allowed to form for 5–7 days and subsequently
fixed and stained with 2% crystal violet dissolved in 1:3
methanol and 2:3 acetic acid (v:v). Colonies (>50 cells)
were scored and quantified using the “Analyze Particles”
plug-in of ImageJ (imagej.nih.gov/ij/). Experiments were
performed three times.
Wound-healing assay
Cell migration was assessed with the OrisTMCell Migration
Assembly Kit (AMS Biotechnology). Cells were seeded in
96-well plates containing cell stoppers (which create a
2 mm central circle) and left to attach overnight. There-
upon, cell stoppers were removed and cells were treated
as indicated. Pictures were captured at baseline and after
48 h using a Leica DC 300 F microscope. Images obtained
from at least three independent experiments were quanti-
fied with the ImageJ software (imagej.nih.gov/ij/). Results
are presented as number of invading cells for NIH3T3
cells (scattering invasion pattern) or as percentage of
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wound-closure relative to baseline for HNC cell lines
(pushing-front invasion pattern).
In vivo tumor growth delay experiments and generation
of organotypic tissue cultures
All animal experiments were conducted in strict compli-
ance with Swiss Federal guidelines. Vector and PIK3-
CAH1047R-transfected NIH3T3 METM1268T cells were
injected subcutaneously in both flanks of 7 to 9 weeks-old
female nude mice (RjOrl:NMRI-Foxn1nu/Foxn1nu, Janvier
Labs, Le Genest-Saint-Isle, France). Tumor growth was
estimated by regular caliper measurements using the
following formula:
V ¼ L x W 2 =2
where V = tumoral volume, L = larger dimension and W
= shorter dimension. Upon tumors reaching an average
of 150–200 mm3, animals were randomly allocated to
one of four treatment groups (four animals per group):
vehicle (Solutol HS 15, BASF ChemTrade GmbH), tepo-
tinib 50 mg/kg alone, pictilisib 50 mg/kg alone, and
combination of both drugs. Drugs were administered via
oral gavage and daily measurements were recorded.
Animals were euthanized 4 h after the last treatment,
either at the scheduled endpoint or prematurely when
interruption criteria were met (tumor volume superior
to 1 cm3 or persistent tumor bleeding). For determin-
ation of in vivo proliferation, 5-bromo-2′-deoxyuridine
(BrdU; 2 mg dissolved in 0.9% NaCl) was injected intra-
peritoneally 4 h before euthanasia.
As a complementary assessment method, we generated
organotypic tissue cultures as previously described [31]
from freshly removed fragments of vehicle-treated tu-
mors in each group.
Generation of tissue arrays, BrdU incorporation in vivo,
and immunofluorescence
Tumor xenograft tissue arrays of 5 mm were generated
using the EZ-TMA Manual Tissue Microarray Kit 4 (IHC
World). Sections of 5 μm were then cut, deparaffinized
and rehydrated. Antigen retrieval was performed by heat-
ing slides for 10 min in a microwave oven (600–700 W) in
Tris-EGTA buffer (pH 9.0). Sections were incubated
overnight at 4 °C with specific primary antibodies: BrdU
(1:300), pS6 (1:800), and p-MET (1:150). BrdU was pur-
chased from Abcam and the remaining antibodies from
Cell Signaling Technology.
Slides were washed and incubated with secondary
antibodies from Life Technologies (goat anti-rabbit 488
and goat anti-rat 555), 1:500, for 1 h at room temperature.
Slides were scanned using the Pannoramic Midi digital
slide scanner and analyzed by CellQuant software
(3DHISTECH Ltd).
Data analysis
Statistical analysis and graphic representation of data was
performed with GraphPad (version 5.03). Data are pre-
sented as relative averages ± SD or fold-induction ± SD, as
indicated. Statistical comparisons were performed using
the Mann-Whitney U-test unless otherwise reported.
Tumor sizes were compared by one-way ANOVA.
Statistical significance was set at p < 0.05. Definitions for
p-values are as follows throughout the manuscript: *p =
0.01–0.05, **p = 0.001–0.01, ***p < 0.001. Absence of labels
implies non-significant differences.
Results
PIK3CAE545K and PIK3CAH1047R hotspot mutations confer
resistance and lead to sustained pathway activation upon
MET inhibition in MET-driven in vitro models
We first sought to assess the impact of PIK3CA muta-
tions in models mimicking clinical scenarios featuring
MET constitutive activation, such as gastric or lung
cancer [32, 33]. For this purpose, we used NIH3T3 cells
stably expressing METM1268T. Ectopic expression of
METM1268T leads to constitutive MET kinase activation
and results in high sensitivity to MET inhibitors such as
tepotinib or SU11274 [25, 34].
NIH3T3-METM1268T cells were subsequently transfected
with vectors containing the two commonest PIK3CA
mutations encountered in human cancer: PIK3CAE545K
(helical domain) and PIK3CAH1047R (kinase domain). Cells
transfected with the empty pBabe vector (termed hereafter
‘vector cells’) were used as control (Additional file 1:
Figure S1A). At baseline conditions, cells expressing the
PIK3CAE545K mutation (E545K cells) displayed increased
proliferation relative to vector cells and PIK3CAH1047R
mutant cells (H1047R cells) (p-values 0.02 and 0.006,
respectively), while H1047R cells proliferated slower than
vector cells (p = 0.003; Additional file 1: Figure S1B). Such
observation parallels previous findings in NIH3T3-
METM1268T harboring KRAS mutations, and could be
the result of co-expressing two strongly active oncogenes
in cellular systems. EC50 values for tepotinib and pictilisib
in all three cell lines are provided in Additional file 1:
Figure S1C (discussed below).
We next tested the effects of single and dual MET/
PI3K inhibition on phosphorylation of the MET recep-
tor and two PI3K pathway downstream effectors,
namely AKT and S6. Somewhat surprisingly, levels of
p-AKT were not increased by the overexpression of ei-
ther E545K or H1047R (Fig. 1a-c). While some previous
publications focusing on breast cancer indeed evidenced
increased levels of p-AKT in E545K/H1047R [17, 26],
works studying lung cancer did not show increased p-
AKT levels in tumors expressing H1047R [18]. Previous
data therefore indicate it is possible that PIK3CA muta-
tions lead to different effects on downstream signal
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transducers in different tumor models. As expected,
tepotinib at a concentration of 50 nM fully abrogated
MET phosphorylation at the tyrosine kinase domain
residues (Y1234/1235) in NIH3T3-METM1268T cells re-
gardless of PIK3CA status (Fig. 1a). Increasing concen-
trations of tepotinib led to downregulation of AKT
phosphorylation in vector and E545K cells and to a
lesser extent in H1047R cells (especially 100 nM of
tepotinib), but S6 phosphorylation could only be abro-
gated in vector cells at this range of concentrations
(Fig. 1a). PI3K inhibition by pictilisib was similarly
effective in reducing p-AKT levels in these three cell
lines, but at a concentration of 100 nM p-S6 levels were
lower in cells harboring PIK3CA mutations (Fig. 1b).
Combination of both drugs led to a more effective de-
phosphorylation of AKT and S6 in PIK3CA-mutated
cells (Fig. 1c).
We next explored whether the differences seen in
signaling upon MET inhibition had an impact on rele-
vant biological endpoints such as proliferation, cell-
death induction, and wound-healing ability. Along the
lines of a previous study [25], MET inhibition led to
drastic reduction of around 90% in cell proliferation in
vector NIH3T3 METM1268T cells at a concentration of
50 nM (Fig. 2a). Conversely, cells harboring PIK3-
CAH1047R but not PIK3CAE545K were significantly more
resistant to single MET inhibition (Fig. 2a). Co-targeting
PI3K by pictilisib along with tepotinib resulted in signifi-
cantly further reduction of proliferation in all three cell
lines (Fig. 2a). Excess over bliss value determinations
however were higher and systematically significant only
in cell lines harboring PIK3CA mutations, indicating
stronger synergism between MET and PI3K inhibition in
PIK3CA-mutated cells (Fig. 2b).
Induction of cell death was assessed through caspase-3
enzymatic activity determination and by performing live/
dead assays (Fig. 2c and d). Both assays demonstrated
that E545K and especially H1047R cells displayed signifi-
cant resistance to cell death induction upon single MET
inhibition (Fig. 2c). Single PI3K inhibition did not lead
to significant cell death induction (relative to DMSO-
treated controls whose value would be 1) in any of the
three cell lines, but co-targeting MET and PI3K led to
significantly higher levels of cell death in all cell lines
(Fig. 2c).
Given the incongruence seen in E545K cells between
proliferation assays and EC50 values (suggesting sensitiv-
ity to MET inhibition), and the findings resulting from
immunoblots and cell death assays (suggesting resist-
ance), we performed colony-forming assays over a period
of 7 days in order to avoid the differences potentially
due to the substantially higher proliferation rate of
E545K with respect to vector and H1047R cells. These
assays confirmed significant resistance of both E545K
and H1047R cells upon MET inhibition when compared
to vector cells. Resistance was successfully reversed by
co-targeting PI3K (Fig. 3a).
In addition, wound-healing assays demonstrated that
single MET inhibition led to significant reduction of
wound-healing in vector cells, but not in those harboring
PIK3CA mutations (Fig. 3b). Single PI3K inhibition did
not significantly alter wound-healing in any of the three
cell lines, while combination treatment re-established
sensitivity to MET inhibition in E545K and H1047R cells
to levels comparable to vector cells (Fig. 3b).
PIK3CAH1047R mutation induces resistance to tepotinib in
a subcutaneous in vivo xenograft model and can be
overcome by a dual MET/PI3K inhibition
As next step, in order to validate in vitro findings in a
more complex model, we generated subcutaneous xeno-
grafts with NIH3T3-METM1268T cells transfected with ei-
ther the empty pBabe vector or PIK3CAH1047R. Based on a
pilot experiment (data not shown), the number of cells
Fig. 1 Effects of single and dual MET/PI3K inhibition on phosphorylation
of PI3K downstream targets AKT and S6 after 16 h of treatment. a, single
treatment with increasing concentrations of MET inhibitor tepotinib
(0-100 nM); b, PI3K inhibitor pictilisib (0-100 nM). c, single vs. dual
MET/PI3K inhibition
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injected was 500,000 for vector cells and 100,000 for
H1047R cells. Tumors in the H1047R group reached an
average volume of 150 mm3 17 days after injection, versus
24 days in the vector group (Fig. 4a).
Treatments were administered following a previously-
described schedule of 5 consecutive days, followed by a
2-day hiatus, and five more days of treatment (Fig. 4a)
[25]. Confirming our previous results [25, 35], xeno-
grafts generated from vector cells underwent tumor
shrinkage within the three first days of treatment with
tepotinib, without any subsequent re-growth (Fig. 4b
and c). Conversely, while some of the H1047R tumors
initially underwent moderate remission under tepotinib,
all tumors regained and outgrew their initial size. Co-
targeting PI3K in these tumors restored sensitivity to
tepotinib (Fig. 4b and c). Single PI3K inhibition did
only have a significant effect in H1047R.
Comparison of average tumor sizes of vector vs.
H1047R at the experimental endpoint showed significant
resistance to tepotinib in H1047R tumors (p = 0.012), as
well as higher efficacy of pictilisib in the same group
(p = 0.026; Fig. 4d).
Morphological evaluation of extracted tumors via H&E
staining displayed massive cell loss in vector tumors
treated with tepotinib alone. This was in strong contrast
to H1047R tumors, which were morphologically similar to
vehicle-treated controls (Fig. 4e).
We next assessed proliferation using in vivo BrdU uptake
(Fig. 4f), confirming that tepotinib alone had a marked ef-
fect on vector but not H1047R tumors (p = 0.016). H1047R
Fig. 2 Differential effects on cell proliferation and cell death of single and dual MET/PI3K inhibition in MET-driven models with and without
PIK3CA mutations. a, cell proliferation was assessed after 72 h of treatment using a resazurin-reduction based assay. b, combination effects
were estimated by calculating excess over the bliss. Bold-italic numbers indicate values significantly different to 0 according to one-sample
t-test (=0 additivity, >0 effect more-than-additive, <0 less-than-additive). c, caspase-3 enzymatic activity was measured using a specific fluorogenic
substrate after 72 h of treatment. Comparisons of single tepotinib treatment vs. combination treatment were significant in all cell lines: vector
(p = 0.0451), E545K (p < 0.001), and H1047R (p = 0.004). d, representative images (20x magnification) of viable (calcium AM, green) and dead
(ethidium homodimer, red) cells. Lower panel: percentage of dead cells in each treatment condition
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tumors treated with pictilisib alone displayed a significantly
higher percentage of BrdU positive nuclei (p = 0.022;
Fig. 4f). It is important noting that only one of all extracted
tumors treated with combination therapy in the vector-
transfected group had some cellular content that could be
further assessed.
From a biochemical perspective, in contrast to vector
xenografts, H1047R xenografts displayed preserved levels
of p-S6 upon single MET inhibition (Additional file 2:
Figure S2A), p-AKT levels were similar to those described
in vitro (Additional file 2: Figure S2B).
Finally, we evaluated levels of p-AKT in ex vivo organo-
typic tissue cultures generated from a fragment of freshly-
harvested tissue from vehicle-treated animals and subject
to the same in vitro treatments detailed above for 3 days.
The results in this model confirmed sustained AKT phos-
phorylation upon MET inhibition in H1047R-derived cul-
tures already at this earlier time-point (Additional file 2:
Figure S2C).
Dual blockade of MET and PI3K in non-MET-driven HNC
cell lines harboring endogenous PIK3CA mutations
In order to further elucidate the impact of PIK3CA muta-
tions in the context of MET-targeted inhibition in a model
that did not display constitutive receptor activation, we
used a panel of three MET-expressing but non-MET-
driven HNC cell lines. Two of these harbor PIK3CA
mutations: Detroit-562 (H1047R) and SCC-61 (E542K)
[28, 29]. FaDu cells harbor wild-type PIK3CA, and all cell
lines express the MET wild-type receptor [4, 28]. EC50
values for tepotinib and pictilisib in these cell lines are
shown in Additional file 3: Figure S3.
While basal expression of p-MET was variable in these
three cell lines, stimulation with MET ligand SF/HGF
led, as expected, to receptor activation in all cases. MET
phosphorylation could be effectively inhibited with 50
nM of tepotinib, with variable but usually moderate
effects on p-AKT (Fig. 5a). To determine the effects of
single and dual MET/PI3K inhibition on PI3K down-
stream effectors AKT and S6, cells were treated with half
of the EC50 concentrations of tepotinib (FaDu: 0.06 μM,
Detroit-562: 0.67 μM, and SCC-61: 0.47 μM) and pictili-
sib (FaDu: 0.64 μM, Detroit-562: 0.76 μM, and SCC-61:
0.11 μM). Combination treatment led to more effective
abrogation of AKT phosphorylation than either tepotinib
or pictilisib alone, but p-S6 levels were generally unaltered
(Fig. 5b).
We anticipated that since both MET and PI3K signaling
contribute to cell proliferation, combination of inhibitors
of these pathways would lead to either additive or
Fig. 3 Presence of PIK3CA mutations confers resistance in colony-forming assays and wound-healing upon MET inhibition. a, colony-forming
assays (left: relative colony quantification; right: representative images). b, wound-healing assays. Cell contours were enhanced for clarity using
the Paint.NET software. P-values represent comparisons between treatment conditions and vehicle-treated controls
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Fig. 4 Presence of PIK3CAH1047R mutation confers resistance to MET-targeted inhibition in a subcutaneous xenograft model. a, in vivo experimental
design. Nude mice were treated via oral gavage with tepotinib 50 mg/kg alone, pictilisib 50 mg/kg alone, or combination of both drugs for 5
consecutive days, followed by a hiatus of 2 days, and 5 more days of treatment. Mice were euthanized 4 h after the last oral gavage.
b, representative images at experimental endpoint of tumors in situ and immediately after extraction. c, tumor growth delay curves of xenografts
generated with vector and H1047R cells (“§” indicates early interruptions due to tumor size and/or bleeding). Daily sizes of individual tumors were
normalized to their size at the beginning of treatment (here reported as size relative to baseline ± SD). d, comparison of tumor sizes in the four
treatment conditions at endpoint. e, morphological assessment of tumors by H&E staining. f, BrdU uptake in vivo and quantification of positive nuclei
(quantification in vector-transfected group/combination treatment: only one tumor could be evaluated due to a loss of cellular content in the other
tumors; p-value not calculated)
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synergistic effects. To determine the combination effects
of tepotinib and pictilisib, cells were treated with decreas-
ing half-log concentrations of each drug alone, as well as
with combinations of both. Resazurin-reduction assays
were performed and the data were subsequently analyzed
using the excess over bliss method [30]. As shown in
Fig. 5c, combinations of MET and PI3K inhibitors indeed
led to additive and synergistic effects in all three cell lines,
but excess over bliss values tended to be higher in cells
harboring PIK3CA mutations (Detroit-562 and especially
SCC-61).
Combinatorial effects were further assessed using
colony-forming assays for 7 days in the presence of half-
EC50 concentrations of tepotinib and pictilisib. These
assays showed that in presence of single MET inhibition,
colony-forming ability was superior in Detroit-562
(H1047R) than either FaDu or SCC-61 cells (Fig. 6a).
Combination treatment was only superior to either single
MET or PI3K inhibition in Detroit-562 cells (p = 0.035;
Fig. 6a). Remarkably, we observed that single PI3K inhib-
ition had a significantly higher impact on colony-forming
ability than MET inhibition alone in all three cell lines
(Fig. 6a).
Finally, we explored the effect of single vs. dual MET/
PI3K blockade on wound healing in the presence or not
of MET ligand SF/HGF (Fig. 6b). SF/HGF at a concen-
tration of 50 ng/mL was added for 6 h and, after this
period, drugs or vehicle were added without removing
SF/HGF. Cells were incubated for an additional 48 h.
Photo-documentation was obtained at hour 0 (immedi-
ately after removal of stoppers) and at hour 48 (end-
point). Impact of single MET inhibition was moderate
and related to intrinsic cell line wound-healing ability
(no significant differences within each cell line between
MET inhibition in absence or presence of SF/HGF).
Single PI3K inhibition in absence of SF/HGF was most
effective in Detroit-562 cells, but did not affect SF/HGF-
induced wound-healing in any of the cell lines. Combin-
ation of MET and PI3K inhibition was more effective
than single inhibition of either target in the three cell
lines, this observation being particularly prominent in
Detroit-562 (Fig. 6b).
Discussion
The developments in the field of molecular targeted
therapy have led to an unparalleled range of opportun-
ities to therapeutically target a considerable number of
oncogenes or oncogenic pathways in a variety of human
cancers. In spite of the attractive rationale behind mo-
lecular targeted therapy and promising preclinical data,
clinical experience has clearly shown that single target
inhibition is rarely effective. As a case in point, single
use of EGFR inhibitors does not lead to significant
tumor remission or prolonged stabilization rates in
unselected patients with colorectal cancer, non-small cell
lung cancer, breast cancer, or HNC among other entities
[29, 36–39].
Fig. 5 Impact of single vs. dual MET/PI3K inhibition on downstream signaling and cell proliferation in non-MET-driven HNC models. a, cells were
serum-starved for 24 h, treated with tepotinib for 2 h, and then stimulated with the MET ligand SF/HGF for 10 min. b, cells were treated for 16 h
with half-EC50 concentrations of tepotinib and pictilisib, alone and in combination, and then lysed. c, cells were treated for 72 h with single or
dual MET/PI3K inhibitors at various concentrations. Cell proliferation was assessed using a resazurin-reduction based assay and combinatorial
effects were determined using the excess over bliss, with values above 0 indicating more-than-additive effects (bold-italic numbers indicate values
significantly different to 0 according to one-sample t-test)
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Emerging and established evidence currently shows
that a major element hindering effective development
and clinical implementation of anti-RTK targeted ap-
proaches is the presence of genomic alterations, mainly
mutations, in cellular signal transduction pathways
[40]. The clearest example, as mentioned above, is the
predictive value of pre-therapeutic screening of KRAS
mutations in patients with colorectal cancer prior to
cetuximab therapy, an approach allowing individually-
tailored therapeutic strategies [10, 11].
In addition, it has been clearly established that aberrant
activation of members in the MAPK or the PI3K pathways
result in resistance to EGFR inhibitors. For instance,
Wang et al. [41] demonstrated that both PIK3CA and
KRAS mutations resulted in resistance to cetuximab
when ectopically expressed in initially-sensitive cells. Co-
targeting mTOR with rapamycin or everolimus led to suc-
cessful sensitivity restoration. Along the same lines, Young
et al. [29] found that cell lines harboring PIK3CA muta-
tions were generally more resistant to EGFR inhibitors
such as erlotinib or gefitinib. Co-targeting EGFR and PI3K
resulted in enhanced tumor growth control in vivo than
either inhibitor alone. Moreover, with respect to MET sig-
naling, we recently demonstrated that HRAS and KRAS
mutations confer differential degrees of resistance to MET
tyrosine kinase inhibitors in MET-expressing preclinical in
vitro and in vivo models [35].
This ensemble of observations further stresses the
importance of pre-therapeutic molecular stratification.
Relevant to this point, recent comprehensive genomic
Fig. 6 Impact of single and dual MET/PI3K blockade on colony-forming and wound-healing ability. a, colony forming assays in presence of EC50
concentrations for each drug (left: colony quantification; right: representative images). b, wound-healing assays. Cells were plated in complete
medium and left to attach overnight in the presence of stoppers that create a central area of 2 mm. Stoppers were removed and cells were
treated with vehicle (medium) or SF/HGF for 6 h. After this period, drugs were added to the medium and wound-healing was evaluated at 48 h
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approaches have revealed variable prevalence rates of
mutations affecting PI3K and MAPK pathways in different
cancers. These results have major implications for imple-
menting rational combinatorial approaches in specific can-
cer types. The Cancer Genome Atlas (TCGA) datasets
available at the cBio Portal for Cancer Genomics (http://
www.cbioportal.org/public-portal/cross_cancer.do; [42, 43])
reveal KRAS mutation rates of over 90% in pancreatic
cancer versus PIK3CA mutation rates below 10%. In con-
trast, entities such as breast cancer or HNC display a pre-
dominance of PIK3CA mutations (around 40%, for an
overall mutation rate of KRAS, NRAS and HRAS inferior
to 5% in both cases). An intermediate group with prevalent
mutations on both pathways would include endometrial
carcinoma (PIK3CA 57%, KRAS 21%), colorectal adenocar-
cinoma (PIK3CA 31%, KRAS 51%), or gastric adenocarcin-
oma (PIK3CA 24%, KRAS 16%).
These figures are globally rendered more complex when
considering different subgroups of patients with different
subtypes of a same cancer entity. With respect with breast
cancer for instance, KRAS mutation rate in metastatic
breast cancer was estimated at approximately 12% [44].
Along the same lines, KRAS mutations were detected in
only 2% of luminal A versus 17.4% in luminal B breast
cancer [45], suggesting accumulation of KRAS mutation
in more aggressive forms of disease.
Another important aspect is that different tumor en-
tities have variable degrees of dependence on signaling
inputs from given RTKs. For this reason, in the present
study we sought to assess differences between models
featuring MET constitutive activation and models with
ligand-induced activation. Our findings indicate that
ectopically-expressed PIK3CA hotspot mutations confer
resistance to MET inhibition in initially-sensitive MET-
driven models, both in vitro and in vivo. In ligand-
dependent HNC cellular models, dual MET and PI3K
blockade was superior to single inhibition on downstream
signaling and wound-healing ability. Importantly however,
stronger synergism between MET and PI3K inhibition was
observed only in HNC cells harboring PIK3CA mutations.
Importantly, the effect of MET inhibition was not only
restored but also enhanced by co-targeting PI3K in both
sets of models.
The differences seen between MET-driven models and
non-MET-driven models endogenously harboring PIK3CA
mutations are most relevant also in terms of pre-
therapeutic stratification. It is increasingly evident that
human cancers and their derived preclinical models
display differential degrees of dependence on signaling
by specific RTKs as well as other kinases. Therefore,
while some malignancies quite uniquely rely on one
given RTK, the same is not true for some other cancer
types. For instance, with respect to MET, McDermott
et al. [33] assessed responses to the MET inhibitor
PHA665752 in a panel of 500 cancer cell lines. These
authors identified a subset of highly-responsive cell
lines, predominantly of gastric cancer and NSCLC
origin, that displayed MET-gene amplification and were
extremely sensitive to MET inhibition. Further in the
same direction, small cohorts of patients who experi-
ence drastic and prolonged disease remission after
MET inhibition indicate that at least subgroups of
gastric cancers are indeed strongly dependent on MET
signaling [32, 46]. Such reliance on a given oncogene
has been termed oncogene addiction [47]. Classically,
oncogene addiction has been associated with underlying
gene amplification, but other types of aberrations such as
activating mutations may also be the cause of RTK-driven
cell growth, transformation, and responses to molecular
targeted therapy [5]. Most illustrative of this point is the
existence of EGFR mutations which determine both de-
pendence on EGFR signaling and responses to EGFR inhib-
itors in patients with lung cancer [48].
In contrast, entities like HNC do not feature oncogene
addiction for any given RTK, and tend to rely more on
ligand-receptor oncogenic loops, as well as on RTK cooper-
ation and redundant signaling [4, 24, 49].
Our study also underlines significant differences in
the way H1047R and E542K/E545K influence responses
to MET inhibition. As mentioned above, while it has
been previously shown that H1047R has a superior
oncogenic potential than E545K in transgenic mam-
mary cancer models [17], the potential of different
PIK3CA mutations in conferring resistance to upstream
inhibition has not been previously explored. Our current
results indicate that PIK3CAH1047R is a stronger effector
of resistance to MET inhibitors, but further translational
studies should address this issue given the variable preva-
lence of helical or catalytic domain mutations seen in
different human malignancies (http://www.cbioportal.org/
public-portal/cross_cancer.do, [42, 43]).
Specifically regarding the potential relevance of MET/
PI3K combinations, in the context of a retrospective re-
view of over 2000 patients, Maryam et al. [50] reported
frequent MET-PI3K co-mutations in colorectal adeno-
carcinoma, thyroid carcinoma, breast adenocarcinoma,
and HNC. To our knowledge, only one study previously
focused on combinations of ARQ 197 (MET inhibitor)
and NVP-BEZ235 (dual PI3K/mTOR inhibitor) in malig-
nant pleural mesothelioma, suggesting a benefit of this
combinatorial approach [51]. This study however did
not assess the impact of PIK3CA mutations on MET
inhibition.
Our current study provides evidence for the first time
supporting the notion of co-targeting MET and PI3K as
a potential therapeutic strategy in common clinical
scenarios, featuring both constitutive and ligand-induced
MET activation along with PIK3CA mutations.
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While the combinatorial strategy we evaluate here could
be therapeutically exploited, it is crucial that upcoming
clinical trials consider the characteristics described above,
namely mutational status of downstream signaling path-
ways and activation status of selected RTKs, in order to
identify the subgroups of patients most likely to benefit
from treatment.
Conclusions
MET, the receptor tyrosine kinase (RTK) for scatter
factor/hepatocyte growth factor, is involved in acquisition
and maintenance of critical oncogenic and invasive fea-
tures in several types of human cancer and represents a
promising molecular therapeutic target. In parallel, accu-
mulating evidence supports the notion that intracellular
signaling pathways downstream of RTKs, such as the
PI3K pathway, constitute potential sources of resistance to
RTK-targeted cancer therapy. Along the same lines,
PIK3CA activating mutations are widespread in cancer. In
this study we have examined the impact of common
PIK3CA helical and catalytic domains hotspot mutations
upon MET inhibition in preclinical MET-driven and head
and neck cancer models, providing therefore a first evalu-
ation of MET targeting in the context of common PI3K
mutations. The results suggest a potential added benefit of
this combinatorial approach in common clinical scenarios
featuring aberrant MET activation and PIK3CA muta-
tions, warranting evaluation in upcoming clinical trials.
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Additional file 1: Figure S1. Generation of NIH3T3 METM1268T PIK3CA-
mutated cell lines. A, transfection and expression of mutated variants
E545K and H1047R was confirmed by detection of the HA tag after
immunoprecipitation of HA and detection of p110α. B, comparison of
cell proliferation in cells transfected with control vector, pBabe-E545K,
and pBabe-H1047R. C, dose-response plots upon exposure to tepotinib
and pictilisib and EC50 values with 95% confidence intervals (CI) for
both drugs. (PNG 108 kb)
Additional file 2: Figure S2. Resistance to MET inhibition in H1047R
tumors in vivo is accompanied by sustained PI3K pathway activation. A,
representative images of p-MET and pS6 stained tumors. MET inhibition
(tepotinib 50 mg/kg) effectively abrogated MET phosphorylation both in
vector and H1047R, but decrease in S6 phosphorylation was only seen in
vector tumors. B, immunoblots of AKT in tumoral lysates (two per
condition). Right: determination of densitometric values. C, organotypic
tissue cultures (left) were used to evaluate AKT phosphorylation levels
(center) upon single and dual MET/PI3K inhibition after 3 days of ex vivo
culture. Right: determination of densitometric values. (PNG 4913 kb)
Additional file 3: Figure S3. Sensitivity to MET and PI3K inhibitors in
HNC cell lines. Top: Dose-response plots for EC50 value determination in
FaDu (PIK3CA wild-type), Detroit-562 (PIK3CAH1047R), and SCC-61 (PIK3CAE542K).
Bottom: EC50 values and 95% confidence intervals for MET inhibitor tepotinib
and PI3K inhibitor pictilisib. (PNG 46 kb)
Abbreviations
EGFR: Epidermal growth factor receptor; HGF: Hepatocyte growth factor;
HNC: Head and neck cancer; MAPK: Mitogen-activated protein kinase;
NSCLC: Non-small cell lung cancer; PI3K: Phosphoinositide 3-kinase;
RTK: Receptor tyrosine kinase; SF: Scatter factor
Acknowledgements
The outstanding technical support of Dr. Aurélie Quintin, Mr. Bruno Streit
and Mrs. Melanie Leuener-Tombolini is gratefully acknowledged.
Funding
This study was financially supported by Hedy und Werner Berger-Janser
Stiftung grant (to M.M.), Bernese Cancer League Grant (to M.M.) and by the
Swiss National Science Foundation (grant. no. 31003A_156816 to Y.Z.). These
funding bodies have no role in the design of the study and collection,
analysis, and interpretation of data or in writing the manuscript.
YZ received a drug donation from Merck. Merck had no role in the study
design, the collection and interpretation of data, nor in the writing of this
article. Merck has performed a scientific review of the publication, but the
views and opinions described in the publication do not necessarily reflect
those of Merck.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
LN, RG, DMA, RC, YZ and MM contributed to conception and design of the
study. LN, PH, MP, RC and PF acquired and analyzed the data. LN, PH, RG, DMA,
RC, YZ and MM interpreted data. LN, YZ and MM drafted the manuscript and
LN, RG, DMA, RC, YZ and MM revised it critically for important intellectual
content. All authors gave final approval of the version to be published.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Animal studies reported within the frame of the study were conducted in
strict compliance with Swiss Federal guidelines. Consent to participate is not
applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Clinical Research, Inselspital, Bern University Hospital, and
University of Bern, 3008 Bern, Switzerland. 2Department of Radiation
Oncology, Inselspital, Bern University Hospital, and University of Bern, 3010
Bern, Switzerland. 3Department of Otorhinolaryngology – Head and Neck
Surgery, Inselspital, Bern University Hospital, and University of Bern, 3010
Bern, Switzerland. 4Institute of Biochemistry and Molecular Medicine,
University of Bern, 3012 Bern, Switzerland.
Received: 10 November 2016 Accepted: 10 May 2017
References
1. Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De
Braud F, Tiseo M. Targeting the MET gene for the treatment of non-small-
cell lung cancer. Crit Rev Oncol Hematol. 2014;89:284–99.
2. Avan A, Maftouh M, Funel N, Ghayour-Mobarhan M, Boggi U, Peters GJ,
Giovannetti E. MET as a potential target for the treatment of upper
gastrointestinal cancers: characterization of novel c-Met inhibitors from
bench to bedside. Curr Med Chem. 2014;21:975–89.
3. Miyata Y, Asai A, Mitsunari K, Matsuo T, Ohba K, Mochizuki Y, Sakai H. Met in
urological cancers. Cancers (Basel). 2014;6:2387–403.
4. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali
M, Yala S, Kanteti R, Cohen EE, Lingen MW, et al. The MET receptor tyrosine
kinase is a potential novel therapeutic target for head and neck squamous
cell carcinoma. Cancer Res. 2009;69:3021–31.
5. Zimmer Y, Vaseva AV, Medova M, Streit B, Blank-Liss W, Greiner RH,
Schiering N, Aebersold DM. Differential inhibition sensitivities of MET
Nisa et al. Molecular Cancer  (2017) 16:93 Page 12 of 14
mutants to the small molecule inhibitor SU11274. Cancer Lett. 2010;289:
228–36.
6. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA,
Hansen M, Schaefer E, Naoki K, Lader A, et al. Functional expression and
mutations of c-Met and its therapeutic inhibition with SU11274 and small
interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65:1479–88.
7. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in
cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103.
8. Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in
oncogenesis and drug resistance. Pharmacol Ther. 2014;142:316–38.
9. Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra
L, Jarzab B, Medvedev V, Kreissl MC, et al. Cabozantinib in progressive
medullary thyroid cancer. J Clin Oncol. 2013;31:3639–46.
10. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC,
Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and
benefit from cetuximab in advanced colorectal cancer. N Engl J Med.
2008;359:1757–65.
11. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y,
Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4 treatment
and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.
12. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T. Molecular
determinants of anti-EGFR sensitivity and resistance in metastatic colorectal
cancer. Br J Cancer. 2010;103:1765–72.
13. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and
opportunities. Nat Rev Drug Discov. 2014;13:140–56.
14. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A,
Powell SM, Riggins GJ, et al. High frequency of mutations of the PIK3CA
gene in human cancers. Science. 2004;304:554.
15. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms,
modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7–24.
16. Samuels Y, Diaz Jr LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I,
Rago C, Huso DL, Lengauer C, Kinzler KW, et al. Mutant PIK3CA promotes
cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561–73.
17. Meyer DS, Koren S, Leroy C, Brinkhaus H, Muller U, Klebba I, Muller M,
Cardiff RD, Bentires-Alj M. Expression of PIK3CA mutant E545K in the
mammary gland induces heterogeneous tumors but is less potent than
mutant H1047R. Oncogenesis. 2013;2:e74.
18. Trejo CL, Green S, Marsh V, Collisson EA, Iezza G, Phillips WA, McMahon M.
Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to
promote lung cancer progression. Cancer Res. 2013;73:6448–61.
19. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases
as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–19.
20. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J,
Smrcka AS, Thelen M, Cadwallader K, Tempst P, Hawkins PT. The G beta
gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor,
p101. Cell. 1997;89:105–14.
21. Laplante M, Sabatini DM. mTOR signaling in growth control and disease.
Cell. 2012;149:274–93.
22. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–7.
23. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q,
Du Y, Gilbert BR, et al. Frequent mutation of the PI3K pathway in head and
neck cancer defines predictive biomarkers. Cancer Discov. 2013;3:761–9.
24. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT,
Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, et al. HGF and c-Met
participate in paracrine tumorigenic pathways in head and neck squamous
cell cancer. Clin Cancer Res. 2009;15:3740–50.
25. Medova M, Pochon B, Streit B, Blank-Liss W, Francica P, Stroka D, Keogh A,
Aebersold DM, Blaukat A, Bladt F, Zimmer Y. The novel ATP-competitive
inhibitor of the MET hepatocyte growth factor receptor EMD1214063
displays inhibitory activity against selected MET-mutated variants. Mol
Cancer Ther. 2013;12:2415–24.
26. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic
properties of mutant p110alpha and p110beta phosphatidylinositol 3-
kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;
102:18443–8.
27. Fiordalisi JJ, Johnson 2nd RL, Ulku AS, Der CJ, Cox AD. Mammalian
expression vectors for Ras family proteins: generation and use of expression
constructs to analyze Ras family function. Methods Enzymol. 2001;332:3–36.
28. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP, Su GH.
PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer
Res. 2006;12:1441–6.
29. Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C,
Seiwert TY, Cohen EE. Molecular phenotype predicts sensitivity of squamous
cell carcinoma of the head and neck to epidermal growth factor receptor
inhibition. Mol Oncol. 2013;7:359–68.
30. Goswami CP, Cheng L, Alexander PS, Singal A, Li L. A new drug combinatory
effect prediction algorithm on the cancer cell based on gene expression and
dose-response curve. CPT Pharmacometrics Syst Pharmacol. 2015;4:e9.
31. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A,
Coggi G, Flavin R, et al. Preclinical model of organotypic culture for
pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A.
2010;107:8352–6.
32. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J,
Pandita A, Peterson A, Salgia R. Durable complete response of metastatic
gastric cancer with anti-Met therapy followed by resistance at recurrence.
Cancer Discov. 2011;1:573–9.
33. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J,
Archibald H, Raudales R, Tam A, Lee D, et al. Identification of genotype-
correlated sensitivity to selective kinase inhibitors by using high-throughput
tumor cell line profiling. Proc Natl Acad Sci U S A. 2007;104:19936–41.
34. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D,
Gruber G, Liang C, Howlett AR, et al. The Met kinase inhibitor SU11274
exhibits a selective inhibition pattern toward different receptor mutated
variants. Oncogene. 2004;23:5387–93.
35. Leiser D, Medova M, Mikami K, Nisa L, Stroka D, Blaukat A, Bladt F,
Aebersold DM, Zimmer Y. KRAS and HRAS mutations confer resistance to
MET targeting in preclinical models of MET-expressing tumor cells. Mol
Oncol. 2015;9:1434–46.
36. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer:
understanding resistance to epidermal growth factor receptor inhibitors.
Clin Cancer Res. 2010;16:2489–95.
37. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF,
PIK3CA, and PTEN mutations: implications for targeted therapies in
metastatic colorectal cancer. Lancet Oncol. 2011;12:594–603.
38. Nanda R. Targeting the human epidermal growth factor receptor 2 (HER2)
in the treatment of breast cancer: recent advances and future directions.
Rev Recent Clin Trials. 2007;2:111–6.
39. Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of
non-small cell lung cancer. Oncologist. 2009;14:1116–30.
40. Wood KC. Mapping the pathways of resistance to targeted therapies.
Cancer Res. 2015;75:4247–51.
41. Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS,
Vitale-Cross L, Chen Q, Gutkind JS. mTOR co-targeting in cetuximab
resistance in head and neck cancers harboring PIK3CA and RAS mutations. J
Natl Cancer Inst. 2014;106(9). doi:10.1093/jnci/dju215.
42. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A,
Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an
open platform for exploring multidimensional cancer genomics data.
Cancer Discov. 2012;2:401–4.
43. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y,
Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer
genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
44. Cejalvo JM, Martinez de Duenas E, Galvan P, Garcia-Recio S, Burgues Gasion
O, Pare L, Antolin S, Martinello R, Blancas I, Adamo B, et al. Intrinsic subtypes
and gene expression profiles in primary and metastatic breast cancer.
Cancer Res. 2017;77:2213–21.
45. Pereira CB, Leal MF, de Souza CR, Montenegro RC, Rey JA, Carvalho AA,
Assumpcao PP, Khayat AS, Pinto GR, Demachki S, et al. Prognostic and
predictive significance of MYC and KRAS alterations in breast cancer
from women treated with neoadjuvant chemotherapy. PLoS One.
2013;8:e60576.
46. Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov
M, Bufill JA, Lee C, Jentz D, et al. Activation of MET via diverse exon 14
splicing alterations occurs in multiple tumor types and confers clinical
sensitivity to MET inhibitors. Cancer Discov. 2015;5:850–9.
47. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction–a
rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol.
2006;3:448–57.
48. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim
DW, Chung DH, et al. Predictive and prognostic impact of epidermal
growth factor receptor mutation in non-small-cell lung cancer patients
treated with gefitinib. J Clin Oncol. 2005;23:2493–501.
Nisa et al. Molecular Cancer  (2017) 16:93 Page 13 of 14
49. Singleton KR, Kim J, Hinz TK, Marek LA, Casas-Selves M, Hatheway C, Tan AC,
DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of
fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-
b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte
growth factor receptor drives growth and survival of head and neck
squamous carcinoma cell lines. Mol Pharmacol. 2013;83:882–93.
50. Zenali M, DeKay J, Liu Z, Hamilton S, Zuo Z, Lu X, Bakkar R, Mills G,
Broaddus R. Retrospective review of MET gene mutations. Oncoscience.
2015;2:533–41.
51. Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain
AN, Vigneswaran W, Seiwert T, et al. MET and PI3K/mTOR as a potential
combinatorial therapeutic target in malignant pleural mesothelioma.
PLoS One. 2014;9:e105919.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Nisa et al. Molecular Cancer  (2017) 16:93 Page 14 of 14
